Relmada Therapeutics annual diluted eps
Diluted EPSBasic EPS
2012
2012
2013
2013
2014
2015
2016
2017
2018
2019
2019
2020
2021
2022
2023
2024
2025
Relmada Therapeutics EPS History: Annual & Quarterly (RLMD)
Relmada Therapeutics's diluted EPS was -$1.45 for fiscal 2025.
View full Relmada Therapeutics company overviewRelmada Therapeutics annual diluted eps history
| Fiscal year | Period ended | Diluted EPS | Basic EPS | Change | Growth |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | -$1.45 | -$1.45 | $1.20 | — |
| 2024 | 2024-12-31 | -$2.65 | -$2.65 | $0.63 | — |
| 2023 | 2023-12-31 | -$3.28 | -$3.28 | $2.02 | — |
| 2022 | 2022-12-31 | -$5.30 | -$5.30 | $1.86 | — |
| 2021 | 2021-12-31 | -$7.16 | -$7.16 | -$3.35 | — |
| 2020 | 2020-12-31 | -$3.81 | -$3.81 | -$2.19 | — |
| 2019 · Dec 31 | 2019-12-31 | -$1.62 | -$1.62 | — | — |
| 2019 · Jun 30 | 2019-06-30 | -$2.74 | -$2.74 | $0.12 | — |
| 2018 | 2018-06-30 | -$2.86 | -$2.86 | -$0.78 | — |
| 2017 | 2017-06-30 | -$2.08 | -$2.08 | -$1.04 | — |
| 2016 | 2016-06-30 | -$1.04 | -$1.04 | $7.32 | — |
| 2015 | 2015-06-30 | -$8.36 | -$8.36 | $26.24 | — |
| 2014 | 2014-06-30 | -$34.60 | -$34.60 | — | — |
| 2013 · Dec 31 | 2013-12-31 | -$163.60 | -$163.60 | -$100.20 | — |
| 2013 · Aug 31 | 2013-08-31 | $0.00 | $0.00 | $0.00 | — |
| 2012 · Dec 31 | 2012-12-31 | -$63.40 | -$63.40 | — | — |
| 2012 · Aug 31 | 2012-08-31 | $0.00 | $0.00 | — | — |
Relmada Therapeutics quarterly diluted eps
Diluted EPSBasic EPS
Q2.12
Q3.12
Q1.13
Q1.13
Q2.13
Q3.13
Q1.14
Q4.13
Q1.14
Q1.14
Q1.15
Q2.15
Q3.15
Q1.16
Q2.16
Q3.16
Q1.17
Q2.17
Q3.17
Q1.18
Q2.18
Q3.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q1.20
Q2.20
Q3.20
Q1.21
Q2.21
Q3.21
Q2.22
Q3.22
Q1.23
Q2.23
Q3.23
Q1.24
Q2.24
Q3.24
Q1.25
Q2.25
Q3.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Diluted EPS | Basic EPS | Change | YoY change |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | -$0.11 | -$0.11 | $0.19 | — |
| Q1 2026 | 2026-03-31 | -$0.22 | -$0.22 | $0.36 | — |
| Q3 2025 | 2025-09-30 | -$0.30 | -$0.30 | $0.42 | — |
| Q2 2025 | 2025-06-30 | -$0.30 | -$0.30 | $0.29 | — |
| Q1 2025 | 2025-03-31 | -$0.58 | -$0.58 | $0.14 | — |
| Q3 2024 | 2024-09-30 | -$0.72 | -$0.72 | $0.01 | — |
| Q2 2024 | 2024-06-30 | -$0.59 | -$0.59 | $0.25 | — |
| Q1 2024 | 2024-03-31 | -$0.72 | -$0.72 | $0.15 | — |
| Q3 2023 | 2023-09-30 | -$0.73 | -$0.73 | $0.58 | — |
| Q2 2023 | 2023-06-30 | -$0.84 | -$0.84 | $0.49 | — |
| Q1 2023 | 2023-03-31 | -$0.87 | -$0.87 | — | — |
| Q3 2022 | 2022-09-30 | -$1.31 | -$1.31 | $1.13 | — |
| Q2 2022 | 2022-06-30 | -$1.33 | -$1.33 | $0.23 | — |
| Q3 2021 | 2021-09-30 | -$2.44 | -$2.44 | -$1.39 | — |
| Q2 2021 | 2021-06-30 | -$1.56 | -$1.56 | -$0.83 | — |
| Q1 2021 | 2021-03-31 | -$1.34 | -$1.34 | -$0.62 | — |
| Q3 2020 | 2020-09-30 | -$1.05 | -$1.05 | -$0.67 | — |
| Q2 2020 | 2020-06-30 | -$0.73 | -$0.73 | -$0.23 | — |
| Q1 2020 · Mar 31 | 2020-03-31 | -$0.72 | -$0.72 | -$0.36 | — |
| Q1 2020 · Sep 30 | 2019-09-30 | -$0.38 | -$0.38 | $0.70 | — |
| Q4 2019 | 2019-06-30 | -$0.50 | -$0.50 | — | — |
| Q3 2019 | 2019-03-31 | -$0.36 | -$0.36 | $0.68 | — |
| Q2 2019 | 2018-12-31 | -$1.12 | -$1.12 | -$0.68 | — |
| Q1 2019 | 2018-09-30 | -$1.08 | -$1.08 | -$0.76 | — |
| Q3 2018 | 2018-03-31 | -$1.04 | -$1.04 | -$0.40 | — |
| Q2 2018 | 2017-12-31 | -$0.44 | -$0.44 | -$0.08 | — |
| Q1 2018 | 2017-09-30 | -$0.32 | -$0.32 | $0.24 | — |
| Q3 2017 | 2017-03-31 | -$0.64 | -$0.64 | -$0.04 | — |
| Q2 2017 | 2016-12-31 | -$0.36 | -$0.36 | $0.52 | — |
| Q1 2017 | 2016-09-30 | -$0.56 | -$0.56 | -$2.00 | — |
| Q3 2016 | 2016-03-31 | -$0.60 | -$0.60 | $0.32 | — |
| Q2 2016 | 2015-12-31 | -$0.88 | -$0.88 | -$2.48 | — |
| Q1 2016 | 2015-09-30 | $1.44 | $1.72 | $16.08 | — |
| Q3 2015 | 2015-03-31 | -$0.92 | -$0.92 | -$9.32 | — |
| Q2 2015 | 2014-12-31 | $1.60 | $2.20 | $43.60 | — |
| Q1 2015 | 2014-09-30 | -$14.64 | -$14.64 | -$1.84 | — |
| Q1 2014 · Mar 31 | 2014-03-31 | $8.40 | $39.60 | — | — |
| Q1 2014 · Feb 28 | 2014-02-28 | $0.00 | $0.00 | $0.00 | — |
| Q4 2013 | 2013-12-31 | -$42.00 | -$42.00 | — | — |
| Q1 2014 · Nov 30 | 2013-11-30 | $0.00 | $0.00 | $0.00 | — |
| Q3 2013 | 2013-09-30 | -$12.80 | -$12.80 | — | — |
| Q2 2013 | 2013-05-31 | $0.00 | $0.00 | $0.00 | — |
| Q1 2013 · Feb 28 | 2013-02-28 | $0.00 | $0.00 | $0.00 | — |
| Q1 2013 · Nov 30 | 2012-11-30 | $0.00 | $0.00 | — | — |
| Q3 2012 | 2012-05-31 | $0.00 | $0.00 | — | — |
| Q2 2012 | 2012-02-29 | $0.00 | $0.00 | — | — |
Relmada Therapeutics diluted eps trends
Over the last five fiscal years, Relmada Therapeutics's diluted eps increased from -$3.81 to -$1.45, a change of $2.36. The latest reported quarter, Q2 2026, shows -$0.11.
About the metric
What earnings per share (EPS) means
Earnings per share (EPS) shows how much profit or loss is attributable to each common share. Diluted EPS includes the potential effect of convertible securities, options, and other instruments that could increase the share count, while basic EPS uses the weighted-average common shares actually outstanding.
Calculation and source
SEC-reported diluted and basic EPS
TickerStat displays diluted and basic earnings per share from SEC filings. Historical EPS values are adjusted to the current share basis when SEC-reported stock-split conversion ratios are available; they are not analyst estimates or earnings forecasts. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Relmada Therapeutics source filings ↗